JP2021533199A5 - - Google Patents

Info

Publication number
JP2021533199A5
JP2021533199A5 JP2021529260A JP2021529260A JP2021533199A5 JP 2021533199 A5 JP2021533199 A5 JP 2021533199A5 JP 2021529260 A JP2021529260 A JP 2021529260A JP 2021529260 A JP2021529260 A JP 2021529260A JP 2021533199 A5 JP2021533199 A5 JP 2021533199A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
complex according
transferrin receptor
nucleotides
dmpk
Prior art date
Application number
JP2021529260A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020028861A5 (https=
JP7705793B2 (ja
JP2021533199A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/044987 external-priority patent/WO2020028861A1/en
Publication of JP2021533199A publication Critical patent/JP2021533199A/ja
Publication of JP2021533199A5 publication Critical patent/JP2021533199A5/ja
Publication of JPWO2020028861A5 publication Critical patent/JPWO2020028861A5/ja
Priority to JP2025004577A priority Critical patent/JP7847681B2/ja
Application granted granted Critical
Publication of JP7705793B2 publication Critical patent/JP7705793B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021529260A 2018-08-02 2019-08-02 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 Active JP7705793B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025004577A JP7847681B2 (ja) 2018-08-02 2025-01-14 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862713914P 2018-08-02 2018-08-02
US62/713,914 2018-08-02
US201862779161P 2018-12-13 2018-12-13
US62/779,161 2018-12-13
US201962855761P 2019-05-31 2019-05-31
US62/855,761 2019-05-31
US201962858888P 2019-06-07 2019-06-07
US62/858,888 2019-06-07
US201962859672P 2019-06-10 2019-06-10
US62/859,672 2019-06-10
PCT/US2019/044987 WO2020028861A1 (en) 2018-08-02 2019-08-02 Muscle targeting complexes and uses thereof for treating myotonic dystrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025004577A Division JP7847681B2 (ja) 2018-08-02 2025-01-14 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用

Publications (4)

Publication Number Publication Date
JP2021533199A JP2021533199A (ja) 2021-12-02
JP2021533199A5 true JP2021533199A5 (https=) 2022-08-09
JPWO2020028861A5 JPWO2020028861A5 (https=) 2022-08-09
JP7705793B2 JP7705793B2 (ja) 2025-07-10

Family

ID=69230803

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021529260A Active JP7705793B2 (ja) 2018-08-02 2019-08-02 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用
JP2025004577A Active JP7847681B2 (ja) 2018-08-02 2025-01-14 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025004577A Active JP7847681B2 (ja) 2018-08-02 2025-01-14 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用

Country Status (11)

Country Link
US (1) US20210308272A1 (https=)
EP (1) EP3829596A4 (https=)
JP (2) JP7705793B2 (https=)
KR (1) KR20210081323A (https=)
CN (1) CN112955154A (https=)
AU (2) AU2019314538B2 (https=)
CA (1) CA3108287A1 (https=)
IL (2) IL321905A (https=)
MX (1) MX2021001283A (https=)
SG (1) SG11202100925VA (https=)
WO (1) WO2020028861A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7506601B2 (ja) 2017-12-06 2024-06-26 アビディティー バイオサイエンシーズ,インク. 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3829595A4 (en) 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
WO2021142217A1 (en) * 2020-01-10 2021-07-15 Dyne Thereapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of milck1
AU2021241682B2 (en) * 2020-03-27 2026-02-12 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
KR20230046297A (ko) * 2020-07-23 2023-04-05 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
AU2021318851A1 (en) * 2020-07-23 2023-03-16 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
IL301187A (en) * 2020-09-11 2023-05-01 Arrowhead Pharmaceuticals Inc RNAi agents for suppressing DUX4 expression, preparations containing them and uses thereof
US20240100177A1 (en) * 2020-12-04 2024-03-28 Dyne Therapeutics, Inc. Antibody-oligonucleotide complexes and uses thereof
US20240117356A1 (en) * 2020-12-31 2024-04-11 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
IL309936A (en) 2021-07-09 2024-03-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of dystrophinopathy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
EP4124345A1 (en) * 2021-07-30 2023-02-01 4basebio UK Ltd Nanoparticles for muscle delivery
CA3226457A1 (en) * 2021-07-30 2023-02-02 Amy WALKER Nanoparticles and peptides for the delivery of cargos to muscle cells
EP4396231A1 (en) 2021-09-01 2024-07-10 Biogen MA Inc. Anti-transferrin receptor antibodies and uses thereof
EP4396352A4 (en) 2021-09-01 2025-10-01 Ionis Pharmaceuticals Inc COMPOUNDS AND METHODS FOR REDUCING DMPK EXPRESSION
US20250339553A1 (en) 2022-04-15 2025-11-06 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
WO2025160275A1 (en) 2024-01-24 2025-07-31 Arrowhead Pharmaceuticals, Inc. Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3443976A1 (en) * 2007-06-29 2019-02-20 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
WO2012012467A2 (en) * 2010-07-19 2012-01-26 Isis Pharmaceuticals, Inc. Modulation of nuclear-retained rna
US9610362B2 (en) * 2012-03-16 2017-04-04 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of DMPK
KR102240217B1 (ko) * 2012-09-25 2021-04-14 젠자임 코포레이션 근긴장성 이영양증의 치료용 펩티드-결합 모르폴리노 안티센스 올리고뉴클레오티드
FI2911699T4 (fi) * 2012-10-23 2025-12-09 Synaffix Bv Muokattu vasta-aine, vasta-ainekonjugaatti ja menetelmä niiden valmistamiseksi
TW201536329A (zh) * 2013-08-09 2015-10-01 Isis Pharmaceuticals Inc 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
CN109310765A (zh) * 2016-06-20 2019-02-05 领先基因生物技术股份有限公司 抗体-药物偶联物
MX2019008199A (es) * 2017-01-06 2019-11-25 Avidity Biosciences Llc Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.

Similar Documents

Publication Publication Date Title
JP2021533199A5 (https=)
JP2021533200A5 (https=)
JP2021533197A5 (https=)
JP2025067909A5 (https=)
JP2021532832A5 (https=)
JP2021533198A5 (https=)
JPWO2020028861A5 (https=)
JPWO2020028864A5 (https=)
JPWO2020028857A5 (https=)
JP2022122928A5 (https=)
JP2023179497A (ja) B型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法
JPWO2020028841A5 (https=)
JP2021532831A5 (https=)
JPWO2018129384A5 (https=)
JP2021507686A5 (https=)
JP6060178B2 (ja) 高効率のナノ粒子型二本鎖オリゴrna構造体およびその製造方法
JPWO2021142313A5 (https=)
IL317871A (en) Muscle targeting complexes and their uses for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy
JPWO2020028840A5 (https=)
JPWO2021142227A5 (https=)
CN118201640A (zh) 用于治疗肌养蛋白病的肌肉靶向复合物
CN120282986A (zh) 肌肉靶向复合物及其用于跳读dmd基因的外显子45的用途
JPWO2020028832A5 (https=)
JPWO2022020107A5 (https=)
JPWO2022026152A5 (https=)